"Liquid biopsy" approaches analyzing cell-free DNA (cfDNA) from the blood of cancer patients are increasingly utilized in clinical practice. However, it is not yet known whether cfDNA sequencing from large cancer patient cohorts can detect genomic alterations at frequencies similar to those observed by direct tumor sequencing, and whether this approach can generate novel insights. Here, we report next-generation sequencing data from cfDNA of 1,397 colorectal cancer (CRC) patients. Overall, frequencies of genomic alterations detected in cfDNA were comparable to those observed in three independent tissue-based CRC sequencing compendia.
Abstract
"Liquid biopsy" approaches analyzing cell-free DNA (cfDNA) from the blood of cancer patients are increasingly utilized in clinical practice. However, it is not yet known whether cfDNA sequencing from large cancer patient cohorts can detect genomic alterations at frequencies similar to those observed by direct tumor sequencing, and whether this approach can generate novel insights. Here, we report next-generation sequencing data from cfDNA of 1,397 colorectal cancer (CRC) patients. Overall, frequencies of genomic alterations detected in cfDNA were comparable to those observed in three independent tissue-based CRC sequencing compendia.
Our analysis also identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding of anti-EGFR antibodies. Patients with EGFR ECD mutations displayed striking tumor heterogeneity, with 91% harboring multiple distinct resistance alterations (range 1-13, median 4). These results suggest that cfDNA profiling can effectively define the genomic landscape of cancer and yield important biologic insights.
Significance
This study provides one of the first examples of how large-scale genomic profiling of cfDNA from patients with colorectal cancer can detect genomic alterations at frequencies comparable to those observed by direct tumor sequencing. Sequencing of cfDNA also generated insights into tumor heterogeneity and therapeutic resistance, and identified novel EGFR ectodomain mutations.
Introduction
Next-generation sequencing (NGS) of tumor tissue specimens from large patient cohorts has led to major advances in elucidating the genomic landscape of cancer. Despite the many benefits and therapeutic insights offered by this approach, large-scale genomic profiling through tissue-based sequencing methods is not without limitations. Importantly, to be suitable for sequencing, sampling of primary and metastatic tumor lesions, thereby generating insights into intra-and inter-tumoral heterogeneity (5) (6) (7) (8) (9) (10) (11) (12) . Therefore, understanding the key similarities and differences between cfDNA and tissue-based tumor databases would be informative in determining whether large-scale cfDNA profiling might represent an effective and efficient approach to define the mutational landscape of specific cancer types.
Here, we report results from clinical cfDNA testing of 1,397 de-identified individual patients with advanced colorectal cancer (CRC), and compare these results to three independent large-scale tissue-based sequencing databases.
We find that cfDNA profiling detects genomic alterations at frequencies comparable to those previously reported by direct tumor sequencing. Our findings also reveal how analysis of large cfDNA sequencing databases can provide novel and clinically relevant insights into tumor heterogeneity and therapeutic resistance.
Results

Comparison of the mutational landscape of cfDNA and tumor tissue
To assess the potential utility of a large cfDNA sequencing database, we analyzed 1,772 consecutive blood specimens from patients with CRC who underwent testing with a targeted next-generation sequencing assay (Guardant360 TM , Guardant Health) between 6/1/2014 and 5/18/2016. There were three versions of the assay during the study time period, covering 54, 68, and 70 genes, respectively (Supplementary Table S1 ). In all, 1500 cases (85%) had at least one genomic alteration detectable in cfDNA. Of these, 103 samples represented serial assays from the same patient, leaving 1,397 unique patients with genomic data for analysis (Supplementary Figure S1) .
Research. The prevalence of non-synonymous single nucleotide variants (SNVs) detected in cfDNA was compared to those observed in three publicly available CRC tissue-based databases, including The Cancer Genome Atlas (TCGA) (n=228) (3), the Nurses Health Study/Health Professionals Follow-Up Study (NHS/HPFS) (n=619) (4) , and the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) (n=1,149) (13) . For consistency, the analysis of all cohorts was adjusted to include only those SNVs covered by the cfDNA assay.
Mutational prevalence was largely consistent between the three tissue cohorts (Fig. 1A) , though some small differences were observed, which may be due to expected statistical variability, or to differences in demographics between the three tissue cohorts. For example, the increased prevalence of BRAF mutations in the NHS/HPFS cohort is likely due to the increased representation of women in this cohort (BRAF mutations are more common in women than men with CRC) (Supplementary Table S2 ). Overall, there were striking similarities in mutational prevalence between cfDNA and the three tissue-based databases (Fig. 1A, Supplementary Table S3 ). The mutational prevalence of the twenty most commonly mutated genes in cfDNA was strongly associated with the mutational prevalence in tumor tissue (R 2 = 0.95; p<0.0001) (Fig. 1B) (Fig. 1A) . These differences may reflect real biological differences between the cfDNA and tissue-based cohorts, as patients who received cfDNA profiling were more likely to have metastatic disease and to have received prior therapies.
Additionally, JAK2 V617F mutations were detected in the cfDNA of 16 patients, but none of the 1,996 combined CRC specimens profiled from the tissue-based sequencing databases (Fig. 1C) .
The most likely explanation for this discrepancy is that JAK2 V617F mutations detected in cfDNA were not actually present in the patients' tumors, but were present in a hematopoietic clone of indeterminate clinical potential, which is observed in 0.2% of the general population (14) . Indeed, JAK2 V617F mutations are one of the most common mutations observed in hematopoietic clones of indeterminate clinical potential, and these mutations increase in prevalence with age (15) . Consistent with this hypothesis, the median age for patients with a JAK2 V617F mutation detected in cfDNA was 73 years, whereas the median age among patients without this mutation was 60 years (p=0.0006) (Fig. 1D) . This example highlights an important limitation of blood-based genomic profiling, in that one cannot be certain that a mutation detected in cfDNA is actually derived from the patient's tumor. Still, these data overall show a remarkably high similarity between cfDNAbased and tissue-based profiling, and as a whole support the potential utility and validity of large-scale cfDNA genomic profiling approaches.
Comparison of clonal and subclonal mutations
We then evaluated the clonal versus subclonal landscape of mutation variants detected in the CRC cfDNA cohort. A mutation was defined as "subclonal" if the mutant allele frequency (MAF) was less than 25% of the highest MAF in the sample, and was defined as "clonal" if it was above this threshold. At least one subclonal mutation was found in 51% of patients (range of 1 to 54 subclonal mutations). Among the twenty genes with the highest mutational prevalence in cfDNA, the six genes most likely to be clonal (in order of most to least clonal) include KRAS, FBXW7, APC, SMAD4, BRAF, and TP53 ( Fig. 2A) , all of which are known to play early and critical events in the oncogenesis of CRC.
Furthermore, clonal SNVs were significantly more likely to represent mutations predicted to be activating or inactivating truncal driver mutations, while subclonal SNVs were more likely to be non-functioning "passenger" mutations or variants of unknown significance (OR 3.65, 95% CI 3.24-4.10, P<0.0001) (Fig. 2B ).
Research. We hypothesized that another class of subclonal mutations could represent nontruncal acquired resistance mutations emerging during prior therapy.
Interestingly, EGFR was the gene with the highest percentage of subclonal mutations ( Fig. 2A) . When the MAFs of two predominantly clonal mutations-KRAS and APC-were compared in individual tumors, a linear relationship was observed ( Fig. 2C) , suggesting that these mutations often coexist as clonal events in CRC, although some subclonal KRAS and APC mutations were noted.
However, when the MAFs of EGFR and APC SNVs were compared, a linear relationship was not observed, with most EGFR mutations occurring at subclonal frequencies ( Fig. 2D) . This suggests that the EGFR mutations detected in cfDNA are not likely to be founding clonal events in the development of these CRCs, but rather are likely to be mutations emerging in specific tumor subclones, either as part of the process of tumor progression or metastasis, or perhaps in response to the selective pressure of anti-cancer therapies.
Consistent with this latter hypothesis, many of the patients with subclonal EGFR mutations harbor specific mutations in the extracellular domain (ECD) of EGFR.
EGFR ECD mutations have been implicated in driving clinical acquired
resistance to anti-EGFR antibodies, such as cetuximab and panitumumab, which are approved for the treatment of KRAS and NRAS (RAS) wild type metastatic CRC (7, 12, (16) (17) (18) . Similarly, many of the subclonal KRAS mutations observed also occurred in these same patients with EGFR ECD mutations ( 
EGFR extracellular domain mutations in cfDNA of CRC patients
To evaluate the potential for large-scale cfDNA sequencing to provide clinically relevant insights into therapeutic resistance, we performed a focused analysis on patients with EGFR mutations. In total, 85 of 157 patients with EGFR mutations had mutations in the extracellular domain (amino acids 1 through 649) (Fig 3A) .
To identify mutations with the greatest likelihood of functional relevance, we focused on EGFR ECD mutations that were recurrent (observed in more than one patient) in this cohort. In total, 58 patients harbored a recurrent EGFR ECD mutation, and in 42 patients these EGFR ECD mutations occurred in domain III of EGFR (amino acids 334-504), which represents the binding epitope of both cetuximab and panitumumab (Fig. 3A) . Of these 42 patients, all 24 (57%) patients with available treatment histories were confirmed to have received anti-EGFR antibody treatment prior to blood collection for cfDNA analysis, supporting a likely role for these mutations in driving therapeutic resistance. Treatment histories for the remaining 18 patients were not available.
Analysis of the EGFR ECD mutations from these 42 patients revealed 23 distinct mutations in 11 amino acids in domain III. Seven of these amino acids clustered into two regions-Cluster 2 (I462, S464, G465, K467) and Cluster 3 (K489, I491, S492)-previously reported to be associated with cetuximab and/or panitumumab resistance (Fig. 3A) (7, 10, 12, 18) . Mutations in two amino acids, To explore the hypothesis that V441D and V441G represent novel mechanisms of acquired resistance to anti-EGFR antibodies, we performed molecular modeling to predict the effects of these mutations on cetuximab binding to EGFR.
Compared to wild-type EGFR, the V441D mutation introduces a negatively charged residue that is predicted to decrease the interaction between cetuximab and EGFR (Fig. 3B) . Similarly, the V441G mutation is predicted to destroy a critical hydrophobic node, decreasing the interaction between cetuximab and EGFR (Fig. 3C) . Consistent with these models, both the V441D and V441G EGFR mutants showed significantly reduced binding of both cetuximab and panitumumab, relative to wild type EGFR (Fig. 3D) , supporting their role as novel mechanisms of acquired resistance to anti-EGFR antibodies.
Heterogeneity of anti-EGFR antibody resistance
To further investigate the impact of tumor heterogeneity on therapeutic strategies to overcome anti-EGFR antibody resistance, we performed an in-depth analysis of the cfDNA profiles from the 42 patients with EGFR ECD mutations. In addition to EGFR ECD mutations, multiple mechanisms of acquired resistance to anti-EGFR antibodies that bypass the need for EGFR signaling have been previously
identified, including alterations in KRAS, NRAS, BRAF, MAP2K1, ERBB2, MET,
and KIT (5) (6) (7) (10) (11) (12) 16, 18, (20) (21) (22) (23) (24) (25) . We observed that in 91% of patients with EGFR ECD mutations in cfDNA, at least one additional co-occurring resistance alteration was also detected in cfDNA. On average, these patients harbored 5 distinct resistance alterations to anti-EGFR antibodies (median 4), with as many as 13 co-occurring resistance alterations being detected in a single patient, indicating a striking degree of heterogeneity (Fig. 4A) Figure S2) . Indeed, we observed that patients with EGFR ECD mutations showed an enrichment of subclonal EGFR and KRAS mutations relative to the overall cohort (Figs 2C, D, red labels) . Our analysis also revealed profound heterogeneity occurring in the context of acquired resistance. For example, one patient (Fig 4B, pt #1 ) harbored 13 distinct resistance alterations, including four EGFR ECD mutations, four KRAS mutations, KRAS amplification, two NRAS mutations, ERBB2 amplification, and a downstream mutation affecting MEK1 (encoded by MAP2K1). Another patient (Fig 4B, pt #8 ) harbored eight different resistance alterations, including two EGFR ECD mutations, as well as MET amplification, ERBB2 amplification, KIT amplification, KRAS Q61H, and BRAF V600E. A third patient (Fig 4B, pt #12) harbored seven different resistance alterations, including two EGFR ECD mutations, MET amplification, and KRAS, NRAS, BRAF, and MAP2K1 mutations.
In another patient with serial cfDNA analyses and detailed treatment history, multiple resistance alterations were observed to emerge during anti-EGFR therapy (Supplementary Fig S3) . This degree of heterogeneity and the cooccurrence of multiple distinct resistance alterations present a daunting 
challenge for therapeutic strategies designed to overcome resistance to anti-EGFR antibodies.
In an effort to overcome acquired resistance, anti-EGFR antibody mixtures, such as Sym004 and MM-151, have been developed that are capable of binding multiple epitopes on EGFR and can thereby overcome the effects of individual EGFR ECD resistance mutations. However, these agents may not overcome non-ECD resistance alterations that bypass the requirement for EGFR signaling via activation at other points in the RAS-RAF-MEK-ERK pathway. Importantly, of the 42 patients harboring domain III EGFR ECD mutations identified in our analysis, 88% harbored at least one additional non-ECD resistance alteration detectable in cfDNA that would be predicted to drive resistance to an EGFR antibody mixture alone (Fig. 4C) , with an average of 2.9 non-ECD resistance alterations per patient (range 1-9, median 3).
Discussion
With the growing utilization of clinical cfDNA testing, large cfDNA sequencing databases could represent a valuable resource for genomic discovery. Here, we present one of the first studies assessing whether large-scale genomic profiling of cfDNA can accurately reproduce the genomic landscape of driver mutations defined by direct tumor tissue sequencing studies. In our analysis of the cfDNA profiles of 1,397 patients with CRC, we find that the spectrum and frequency of genomic alterations identified in cfDNA demonstrate a striking similarity with results from three large CRC tumor tissue sequencing cohorts. These data provide a key proof-of-concept supporting the feasibility and validity of largescale genomic analysis of cfDNA. However, cfDNA profiling also has limitations.
In this dataset, genomic alterations in cfDNA were not detected in 15% of cases. This result is similar to rates of cfDNA detection in other CRC series (5, 19) , and is comparable to the rate of tissue insufficiency in tissue-based NGS profiling (2). While it is possible that some patients did not have alterations in genes covered by the NGS assay, in most cases, lack of detection of genomic alterations in cfDNA was likely due to other factors, including low tumor burden, lack of cfDNA shedding by some tumors, and timing of blood collection (ctDNA is reduced after surgical resection and while on active treatment) (26) . Optimizing the timing of cfDNA testing-for example, prior to initiation of therapy or at the time of disease progression-may be an important means of increasing the yield of cfDNA testing.
Another limitation of cfDNA profiling highlighted in our study, is that it is possible for both tumor-derived and non-tumor-derived genomic alterations to be detected in cfDNA, which has the potential to confound analyses (27) . For example, in our study, JAK2 V617F mutations were detected in cfDNA from 1.1% of patients, but in none of the CRC cases from tissue-based cohorts (Fig. 1C) . These JAK2 V617F mutations are most likely derived from a hematopoietic clone of indeterminate clinical potential, which is observed sub-clinically in the peripheral blood in a small percentage of the general population, but with increasing prevalence with age (14) . Indeed, these mutations were found predominantly in older patients in our cohort (Fig. 1D) . Similarly, a recent case report identified an IDH2 mutation in cfDNA from a patient with metastatic CRC that was not readily
Research. detectable in a matched tumor biopsy. The same IDH2 mutation was identified in a bone marrow biopsy, supporting that the alteration originated from a hematopoietic clone (28) . Going forward, methods such as parallel sequencing of mononuclear cells isolated from peripheral blood may help to delineate whether specific alterations detected in cfDNA are derived from clonal hematopoiesis or tumor (27) .
In addition to illustrating the close relationship between the genomic landscape of cfDNA and tissue, our study also offers unique insights into therapeutic resistance. Because tissue-based sequencing compendia rely primarily on early stage and treatment-naïve tumors, these databases have generated limited insights into acquired resistance. Conversely, large cfDNA cohorts, which can more readily provide non-invasive access to patients with advanced disease, may offer unique insight into resistance mechanisms emerging under the selective pressure of systemic therapies. For example, the potential for EGFR ECD mutations to drive resistance to anti-EGFR antibodies has been documented through cfDNA and tumor biopsies from small patient cohorts (7, 10, 12, (16) (17) (18) . These efforts have identified key amino acid mutations that drive acquired resistance, including I462, S464, G465, K467 (Cluster 2) and K489, I491, S492 (Cluster 3) (7, 18) . Our cfDNA database analysis confirmed the recurrent alteration of these previously identified residues, but also identified a previously unreported cluster of EGFR ECD mutations involving V441 and S442 (Cluster 1) that accounted for 25% of all ECD mutations, representing an important and novel mechanism of resistance to EGFR blockade.
A key limitation of our study is the lack of clinical annotation for the cfDNA cohort.
Indeed, since treatment history was not available for some patients with EGFR ECD mutations, it is not possible to confirm that all patients had received prior anti-EGFR antibody therapy. However, EGFR ECD mutations have not been observed in CRC prior to EGFR blockade, and accordingly, in the 57% of EGFR ECD patients with available treatment history, every patient was confirmed to 
have received prior anti-EGFR therapy. While these factors support the likelihood that these alterations emerged in the setting of acquired resistance to anti-EGFR therapy, the absence of paired baseline samples makes this impossible to confirm. Still, it is notable that even without detailed clinical data, this analysis was able to generate new insights into resistance in CRC.
Collectively, these findings demonstrate the potential of large-scale cfDNA profiling as a tool for discovery, and underscore the potential benefits of ongoing academic efforts to create publicly available cfDNA databases with clinical annotation for future studies (29) .
Our study also provides key insights into the role of tumor heterogeneity in the setting of acquired resistance to anti-EGFR antibodies in CRC. Previous studies have illustrated that multiple, heterogeneous resistance alterations can be detected in the cfDNA of individual patients, which are thought to represent the existence of multiple resistant tumor subclones, often residing in different metastases throughout the body (5, 7, 8, 16, 18, 19, 24) . Our study supports the frequent co-occurrence of multiple resistance alterations in individual patients following EGFR blockade, but suggests that the degree of molecular heterogeneity present may be even more profound and complex than anticipated. Indeed, we observed that patients harbored an average of 5 unique resistance alterations (median 4), with as many as 13 distinct resistance alterations observed in a single patient. In only 9% of patients was a single resistance alteration detected.
The degree of molecular heterogeneity observed following anti-EGFR therapy highlights the difficulty of devising a single therapeutic strategy capable of overcoming a broad array of resistance mechanisms, particularly since these alterations frequently affected multiple functionally distinct targets in an individual patient. These findings have profound clinical implications for efforts designed to overcome EGFR ECD mutations by binding multiple epitopes on EGFR (16, 30, 31 
harbor EGFR ECD mutations alone may be exceedingly small-only 12% in this limited series (Fig. 4C) . Therefore, tumor heterogeneity at the time of acquired resistance to EGFR blockade represents a significant obstacle to the development of precision medicine strategies, and suggests that therapeutic strategies that target a key convergent signaling node capable of overcoming the multiplicity of resistant clones present in an individual patient may be required (9, 18) . Collectively, these studies support the potential utility of large-scale cfDNA profiling databases to define the genomic landscape of cancer patients and to provide novel and clinically relevant insights into tumor heterogeneity and therapeutic resistance. Table S1 ).
Subjects provided informed, written consent when appropriate. This research was conducted in accordance with the Declaration of Helsinki and was performed with IRB approval (MDACC LAB09-0373).
Analysis of cfDNA mutational prevalence
To determine cfDNA mutational prevalence, we analyzed samples in which at least one mutation was detected (N= 1,500). When more than one sample was available for the same patient, the most recent sample was selected for analysis.
The final cfDNA analysis cohort included samples from 1,397 unique patients.
Mutations considered in this analysis include single nucleotide polymorphisms that resulted in protein coding changes (ie missense/nonsense). Synonymous, splice site, intron, intergenic, and untranslated region variants were not included in the prevalence calculation. Insertions/deletions (indels), fusions, and amplifications/deletions were also excluded. The primary focus for this analysis is on the twenty genes with the highest mutation prevalence.
Analysis of tissue mutational prevalence
To compare cfDNA mutational prevalence to that of tissue-based datasets, we confidence intervals for binomial proportions were calculated for each gene mutation based on the frequencies and numbers of patients studied using the modified Wald method (32) . CIs were compared descriptively between the cfDNA cohort and each tissue-based cohort. Median age was compared between patients with and without a JAK2 V617F mutation detected in cfDNA using the t-test. Bar charts and scatter plots were used to illustrate the data.
Analysis of clonal and subclonal mutations
The twenty genes with the highest mutation prevalence were analyzed for Research.
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